MX2009006593A - Acetofenonas sustituidas utiles como inhibidores de fosfodiesterasa 4. - Google Patents

Acetofenonas sustituidas utiles como inhibidores de fosfodiesterasa 4.

Info

Publication number
MX2009006593A
MX2009006593A MX2009006593A MX2009006593A MX2009006593A MX 2009006593 A MX2009006593 A MX 2009006593A MX 2009006593 A MX2009006593 A MX 2009006593A MX 2009006593 A MX2009006593 A MX 2009006593A MX 2009006593 A MX2009006593 A MX 2009006593A
Authority
MX
Mexico
Prior art keywords
compounds
represent
independently
haloalkyl
hydroxyalkyl
Prior art date
Application number
MX2009006593A
Other languages
English (en)
Inventor
Jakob Felding
Simon Feldbaek Nielsen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MX2009006593A publication Critical patent/MX2009006593A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de conformidad con la fórmula I: (ver fórmula I) donde X1, X2, X3, X4 y X5, de manera independiente entre sí, representan -CH- o N; o X3, X4 y X5, de manera independiente entre sí, representan -CH- o N, y X1 y X2, independientemente entre sí, representan C y forman parte de un anillo aromático de 6 elementos adicional; R1 representa hidrógeno, alquilo, alquenilo, alquinilo, haloalquilo, hidroxialquilo, o alquilcarbonilo, todos los cuales están opcionalmente sustituidos; R2 y R3, independientemente, representan hidrógeno, -CH2-C(O)NR-R', alquilo, cicloalquilo, alquenilo, cicloalquenilo, alquinilo, haloalquilo, hidroxialquilo, heterocicloalquenilo, alquilarilo, alquilalcoxicarbonilo, alquilcarboniloxi o alcoxialquilo, todos los cuales están opcionalmente sustituidos; R11 representa hidrógeno, halógeno, ciano, amino, alcoxi o alquilamino, X1-X5 representan -CH- o N, que incluye N-óxidos, enantiómeros y diastereómeros; y sus sales aceptables para uso farmacéutico, hidratos o solvatos. La invención se relaciona adicionalmente con procesos para la preparación de los compuestos, con los compuestos para el uso en terapia, con composiciones farmacéuticas que comprenden los compuestos, con métodos para el tratamiento de enfermedades, por ejemplo, enfermedades dermatológicas, con los compuestos; y con el uso de dichos compuestos en la elaboración de medicamentos.
MX2009006593A 2006-12-22 2007-12-21 Acetofenonas sustituidas utiles como inhibidores de fosfodiesterasa 4. MX2009006593A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87168906P 2006-12-22 2006-12-22
US94547007P 2007-06-21 2007-06-21
PCT/DK2007/000564 WO2008077404A1 (en) 2006-12-22 2007-12-21 Substituted acetophenones useful as pde4 inhibitors

Publications (1)

Publication Number Publication Date
MX2009006593A true MX2009006593A (es) 2009-07-02

Family

ID=39156588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006593A MX2009006593A (es) 2006-12-22 2007-12-21 Acetofenonas sustituidas utiles como inhibidores de fosfodiesterasa 4.

Country Status (24)

Country Link
US (3) US8148537B2 (es)
EP (1) EP2125736B1 (es)
JP (1) JP5342451B2 (es)
KR (1) KR101507717B1 (es)
AT (1) ATE503742T1 (es)
AU (1) AU2007336538B2 (es)
BR (1) BRPI0721113A2 (es)
CA (1) CA2673370C (es)
CR (1) CR10877A (es)
CY (1) CY1111596T1 (es)
DE (1) DE602007013617D1 (es)
DK (1) DK2125736T3 (es)
GT (1) GT200900172A (es)
HK (1) HK1135392A1 (es)
HR (1) HRP20110464T1 (es)
IL (1) IL199383A (es)
MX (1) MX2009006593A (es)
MY (1) MY146022A (es)
NO (1) NO20092372L (es)
NZ (1) NZ577863A (es)
PL (1) PL2125736T3 (es)
PT (1) PT2125736E (es)
RU (1) RU2493149C2 (es)
WO (1) WO2008077404A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012015449B1 (pt) 2009-12-22 2021-09-28 Leo Pharma A/S Suspensão de monoidrato de calcipotriol, e, processo para preparar nanocristais de monoidrato de calcipotriol
JP5873439B2 (ja) 2009-12-22 2016-03-01 レオ ファーマ アクティーゼルスカブ ビタミンｄ類似体および溶媒と界面活性剤の混合物を含む皮膚組成物
BR112012015437A2 (pt) 2009-12-22 2016-03-15 Leo Pharma As composição tópica substancialmente anidra de armazenamento estável
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
WO2014083099A1 (en) * 2012-11-30 2014-06-05 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
WO2014096018A1 (en) * 2012-12-19 2014-06-26 Leo Pharma A/S Methods for the preparation of substituted acetophenones
UA121853C2 (uk) * 2013-10-22 2020-08-10 К'Єзі Фармачеутічі С.П.А. Спосіб одержання інгібітору pde4
BR112016029510A2 (pt) 2014-06-23 2017-08-22 Leo Pharma As métodos para a preparação de um composto, e, composto intermediário.
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
WO2017103058A1 (en) 2015-12-18 2017-06-22 Leo Pharma A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
KR101702648B1 (ko) * 2016-05-10 2017-02-03 주식회사 엑티브온 피부 외용제용 보존제, 이를 포함하는 화장료 조성물 및 약학 조성물
MX2019013979A (es) 2017-06-20 2020-07-13 Union Therapeutics As Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (es) * 1992-12-23 1995-11-21 Celltech Ltd
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
KR100445356B1 (ko) * 1995-05-19 2004-11-12 교와 핫꼬 고교 가부시끼가이샤 산소함유헤테로시클릭화합물
AU4967697A (en) * 1996-11-19 1998-06-10 Kyowa Hakko Kogyo Co. Ltd. Oxygenic heterocyclic compounds
CN1761466A (zh) * 2003-03-17 2006-04-19 协和发酵工业株式会社 慢性皮肤疾病的治疗及/或预防剂
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP1888528A2 (en) * 2005-06-10 2008-02-20 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors

Also Published As

Publication number Publication date
HK1135392A1 (en) 2010-06-04
AU2007336538A1 (en) 2008-07-03
GT200900172A (es) 2011-10-05
EP2125736B1 (en) 2011-03-30
CY1111596T1 (el) 2015-10-07
JP2010513334A (ja) 2010-04-30
US8324394B2 (en) 2012-12-04
MY146022A (en) 2012-06-15
DK2125736T3 (da) 2011-07-11
CA2673370C (en) 2015-11-17
CR10877A (es) 2009-07-10
DE602007013617D1 (de) 2011-05-12
IL199383A (en) 2015-02-26
PT2125736E (pt) 2011-07-01
EP2125736A1 (en) 2009-12-02
NZ577863A (en) 2012-04-27
KR20090098990A (ko) 2009-09-18
JP5342451B2 (ja) 2013-11-13
WO2008077404A1 (en) 2008-07-03
US20130012716A1 (en) 2013-01-10
HRP20110464T1 (hr) 2011-07-31
AU2007336538B2 (en) 2012-04-05
NO20092372L (no) 2009-07-14
KR101507717B1 (ko) 2015-04-08
RU2493149C2 (ru) 2013-09-20
CA2673370A1 (en) 2008-07-03
US8148537B2 (en) 2012-04-03
RU2009128191A (ru) 2011-01-27
US20100035908A1 (en) 2010-02-11
US20120165539A1 (en) 2012-06-28
ATE503742T1 (de) 2011-04-15
US8497380B2 (en) 2013-07-30
PL2125736T3 (pl) 2011-09-30
BRPI0721113A2 (pt) 2014-10-07

Similar Documents

Publication Publication Date Title
MX2009006593A (es) Acetofenonas sustituidas utiles como inhibidores de fosfodiesterasa 4.
GB0612423D0 (en) Therapeutic agents
TW200640879A (en) Amide derivatives
GB0226724D0 (en) Therapeutic agents
TW200508180A (en) Therapeutic agents
UA84156C2 (ru) Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
NZ588830A (en) Inhibitors of protein kinases
WO2004074270A3 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
MY153044A (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
HK1138262A1 (en) Novel phosphodiesterase inhibitors
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
GEP20146063B (en) Solid pharmaceutical composition
TW200728291A (en) Amide derivatives
TW200626553A (en) Novel compounds
RS51435B (en) 2- (4-CYANOPHENYL) -6-HYDROXYLAMINOPYRIMIDINE INHIBITING HIV
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
UA96783C2 (ru) Замещенные метилфенилкетоны, пригодные для использования как ингибиторы pde4
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
TW200833696A (en) Spiro-piperidine derivatives
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
AR072810A1 (es) Compuesto de 3-( 4 fenilsulfonil-1-piperazinil) carbonil) pirazolo(1,5 -a) pirimidina , composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento del dolor.
TW200612940A (en) Substituted tetrahydroisoquinolines as mmp inhibitors, process for their preparation and their use as medicament
WO2008044144A3 (en) Chiral tetra-hydro beta-carbolic derivatives and applications thereof as antiparasitic compounds
EA201290487A1 (ru) 5-амино-4-гидроксипентоиламиды

Legal Events

Date Code Title Description
FG Grant or registration